Lundbeck and Merck Sign Exclusive Commercialization Agreement for SYCREST® (asenapine) Sublingual Tablets in All …

Published October 18, 2010

Lundbeck and Merck Sign Exclusive Commercialization Agreement for SYCREST® (asenapine) Sublingual Tablets in All …
WHITEHOUSE STATION, N.J.–(BUSINESS WIRE)–H. Lundbeck A/S (Lundbeck) and Merck, known outside the U.S. and Canada as MSD, today announced a worldwide commercialization agreement for SYCREST® (asenapine) sublingual tablets (5 mg, 10 mg). Under the terms of the agreement, Lundbeck will pay an undisclosed fee as well as product supply payments in exchange for exclusive commercial rights to SYCREST …
Read more on Business Wire

Lundbeck and Merck Sign Exclusive Commercialization Agreement for SYCREST® (asenapine) Sublingual Tablets in All …
H. Lundbeck A/S and Merck, known outside the U.S. and Canada as MSD, today announced a worldwide commercialization agreement for SYCREST® sublingual tablets . Under the terms of the agreement, Lundbeck will pay an undisclosed fee as well as product supply payments in exchange for exclusive commercial rights to SYCREST in all markets outside the United States, China and Japan.
Read more on Business Wire via Yahoo! Finance